CR10699A - Antagonistas de wnt y su uso en el diagnostico y tratamiento de trastornos mediados por wnt - Google Patents

Antagonistas de wnt y su uso en el diagnostico y tratamiento de trastornos mediados por wnt

Info

Publication number
CR10699A
CR10699A CR10699A CR10699A CR10699A CR 10699 A CR10699 A CR 10699A CR 10699 A CR10699 A CR 10699A CR 10699 A CR10699 A CR 10699A CR 10699 A CR10699 A CR 10699A
Authority
CR
Costa Rica
Prior art keywords
wnt
diagnosis
treatment
antagonists
disorders
Prior art date
Application number
CR10699A
Other languages
English (en)
Inventor
James A Ernst
Paul Plakis
Bonnee Rubinfeld
Venita Dealmeida
Original Assignee
Genentech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genentech Inc filed Critical Genentech Inc
Publication of CR10699A publication Critical patent/CR10699A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/71—Assays involving receptors, cell surface antigens or cell surface determinants for growth factors; for growth regulators
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Toxicology (AREA)
  • Biomedical Technology (AREA)
  • Cell Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biotechnology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Hematology (AREA)
  • Microbiology (AREA)
  • Urology & Nephrology (AREA)
  • Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • Plant Pathology (AREA)
  • Oncology (AREA)
  • Epidemiology (AREA)
CR10699A 2006-09-08 2009-03-31 Antagonistas de wnt y su uso en el diagnostico y tratamiento de trastornos mediados por wnt CR10699A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US82506306P 2006-09-08 2006-09-08
US95117507P 2007-07-20 2007-07-20

Publications (1)

Publication Number Publication Date
CR10699A true CR10699A (es) 2009-07-10

Family

ID=39092004

Family Applications (1)

Application Number Title Priority Date Filing Date
CR10699A CR10699A (es) 2006-09-08 2009-03-31 Antagonistas de wnt y su uso en el diagnostico y tratamiento de trastornos mediados por wnt

Country Status (19)

Country Link
US (5) US7947277B2 (es)
EP (1) EP2061495A2 (es)
JP (1) JP2010504081A (es)
KR (1) KR20090060334A (es)
AR (1) AR062709A1 (es)
AU (1) AU2007292242A1 (es)
BR (1) BRPI0714751A2 (es)
CA (1) CA2662041A1 (es)
CL (1) CL2007002609A1 (es)
CR (1) CR10699A (es)
IL (1) IL197240A0 (es)
MA (1) MA31135B1 (es)
MX (1) MX2009002522A (es)
NO (1) NO20091413L (es)
PE (3) PE20120807A1 (es)
RU (1) RU2009113023A (es)
SG (2) SG174100A1 (es)
TW (1) TW200819463A (es)
WO (1) WO2008031009A2 (es)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2500360B1 (en) 2005-10-31 2015-08-05 Oncomed Pharmaceuticals, Inc. Compositions and methods for diagnosing and treating cancer
US7723477B2 (en) 2005-10-31 2010-05-25 Oncomed Pharmaceuticals, Inc. Compositions and methods for inhibiting Wnt-dependent solid tumor cell growth
JP2009065938A (ja) * 2007-09-14 2009-04-02 Matsumoto Shika Univ タンパク質、破骨細胞分化阻害剤、炎症性骨破壊治療薬、遺伝子、組み替えベクター、及びタンパク質の製造方法
EP2235054A1 (en) * 2007-12-13 2010-10-06 Merck Serono S.A. Sarp-1 fusion proteins and uses thereof
WO2009132815A1 (en) 2008-04-30 2009-11-05 Roche Diagnostics Gmbh Use of sfrp-3 in the assessment of heart failure
ES2334092B1 (es) * 2008-07-02 2011-01-24 Proyecto De Biomedicina Cima, S.L. Agentes antiangiogenicos.
EP2331136B1 (en) 2008-09-26 2018-01-10 OncoMed Pharmaceuticals, Inc. Frizzled-binding agents and uses thereof
EP2343080B1 (en) * 2008-09-30 2017-11-08 Kyowa Hakko Kirin Co., Ltd. PHARMACEUTICAL COMPOSITION FOR TREATING BONE DISEASES WHICH COMPRISES PROTEIN COMPRISING Frizzled1, Frizzled2 OR Frizzled7 EXTRACELLULAR CYSTEINE-RICH DOMAIN AND Fc PROTEIN
US9316646B2 (en) 2009-04-23 2016-04-19 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Anti-human ROR1 antibodies
US8877199B2 (en) 2009-05-15 2014-11-04 The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services B cell surface reactive antibodies
US20110189097A1 (en) * 2009-11-09 2011-08-04 Dritan Agalliu Use of WNT inhibitor to inhibit angiogenesis in the CNS
TWI535445B (zh) 2010-01-12 2016-06-01 安可美德藥物股份有限公司 Ｗｎｔ拮抗劑及治療和篩選方法
CN102971337B (zh) 2010-04-01 2016-09-21 昂考梅德药品有限公司 卷曲蛋白结合药剂及其应用
DK2585098T3 (da) 2010-06-28 2014-11-03 Five Prime Therapeutics Inc Ekstracellulære FZD8-domæner og fusionsmolekyler fraekstracellulære FZD8-domæner til anvendelse ved behandling afobesitet og obesitet-relaterede lidelser
UY33469A (es) * 2010-06-29 2012-01-31 Irm Llc Y Novartis Ag Composiciones y metodos para modular la via de señalizacion de wnt
WO2012068299A2 (en) * 2010-11-16 2012-05-24 University Of Southern California Cbp/catenin antagonists for enhancing asymmetric division of somatic stem cells
CA2812785A1 (en) 2010-10-20 2012-04-26 Genentech, Inc. Methods and compositions for modulating the wnt pathway
EP2646469B1 (en) 2010-12-01 2017-11-01 The United States of America, as represented by The Secretary, Department of Health and Human Services Chimeric rabbit/human ror1 antibodies
EP2720721B1 (en) 2011-06-17 2017-08-30 President and Fellows of Harvard College Frizzled 2 as a target for therapeutic antibodies in the treatment of cancer
WO2012176853A1 (ja) 2011-06-21 2012-12-27 協和発酵キリン株式会社 Ｆｒｉｚｚｌｅｄ２の細胞外領域蛋白質のトランケート体を含む蛋白質、および該蛋白質を含有する骨疾患治療用医薬組成物
WO2013012747A1 (en) 2011-07-15 2013-01-24 Oncomed Pharmaceuticals, Inc. Rspo binding agents and uses thereof
US20130216546A1 (en) * 2012-01-10 2013-08-22 Ngm Biopharmaceuticals, Inc. Methods of Treating Glucose Metabolism Disorders
BR112014019741A2 (pt) 2012-02-11 2020-12-22 Genentech, Inc Usos de um antagonista da via wnt, uso de uma terapia anticâncer, método de identificação de um indivíduo com câncer, métodos para prever, método de inibição da proliferação de uma célula de câncer, uso de um antagonista da translocação de r-spondina e antagonista da translocação de r-spondina isolado
KR102149028B1 (ko) * 2012-02-20 2020-08-27 스위디쉬 오르펀 바이오비트럼 에이비 (피유비엘) 인간 보체 c5에 결합하는 폴리펩티드
JP2015536933A (ja) * 2012-10-23 2015-12-24 オンコメッド ファーマシューティカルズ インコーポレイテッド Ｗｎｔ経路結合剤を用いて神経内分泌腫瘍を処置する方法
JP6577868B2 (ja) * 2012-12-19 2019-09-18 アフィボディ・アーベー 新規ポリペプチド
CN105073195A (zh) 2013-02-04 2015-11-18 昂科梅德制药有限公司 使用Wnt途径抑制剂进行治疗的方法及对该治疗的监测
US9168300B2 (en) 2013-03-14 2015-10-27 Oncomed Pharmaceuticals, Inc. MET-binding agents and uses thereof
EP3077546A4 (en) 2013-12-02 2017-04-26 Oncomed Pharmaceuticals, Inc. Identification of predictive biomarkers associated with wnt pathway inhibitors
EP3166627A1 (en) 2014-07-11 2017-05-17 Genentech, Inc. Notch pathway inhibition
KR101572606B1 (ko) 2014-11-24 2015-11-27 강원대학교산학협력단 Sfrp5 유래의 펩타이드 및 이를 포함하는 피부 미백용 화장료 조성물
KR101826841B1 (ko) 2015-02-04 2018-02-08 주식회사 메드팩토 변형된 ｄｋｋ2 단백질 또는 그 유전자를 포함하는 발기부전 예방 또는 치료용 조성물 및 이를 이용한 방법
CA3014498A1 (en) * 2016-03-21 2017-09-28 Children's Medical Center Corporation Compositions and methods for inhibiting wnt signaling
CN108310366A (zh) * 2017-01-15 2018-07-24 复旦大学附属华山医院 重组sfrp5蛋白在制备治疗非酒精性脂肪性肝炎药物中的用途
CN112512556A (zh) 2018-01-16 2021-03-16 儿童医学中心公司 用于抑制wnt信号传导的组合物和方法
US12643947B2 (en) 2019-11-18 2026-06-02 The Regents Of The University Of California Anti-ROR-2 antibodies and methods of use
CA3162518A1 (en) * 2019-11-26 2021-06-03 Cedars-Sinai Medical Center Compositions and methods for treating diseases and conditions by depletion of mitochondrial or genomic dna from circulation
WO2025058052A1 (ja) * 2023-09-14 2025-03-20 国立大学法人神戸大学 グリオブラストーマ細胞の増悪化抑制物質のスクリーニング方法

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2664797A (en) 1996-04-12 1997-11-07 Board Of Trustees Of The Leland Stanford Junior University Wnt receptor compositions and methods
ATE318915T1 (de) 1996-09-24 2006-03-15 Tanox Inc Genfamilie von apoptose-verwandten peptiden, dadurch kodierte peptide und verfahren zu deren herstellung
US6660843B1 (en) 1998-10-23 2003-12-09 Amgen Inc. Modified peptides as therapeutic agents
JP5179689B2 (ja) 2000-02-11 2013-04-10 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツング 抗体ベース融合タンパク質の循環系内半減期の増強
JP2004516812A (ja) 2000-06-21 2004-06-10 インサイト・ゲノミックス・インコーポレイテッド 受容体
US7413873B2 (en) 2001-01-30 2008-08-19 The Regents Of The University Of California Method of detection and treatment of colon cancer
US7713526B2 (en) 2001-05-01 2010-05-11 The Regents Of The University Of California Wnt and frizzled receptors as targets for immunotherapy in head and neck squamous cell carcinomas
US20030044409A1 (en) 2001-05-01 2003-03-06 Carson Dennis A. Immunologic compositions and methods for studying and treating cancers expressing frizzled antigens
AU2002308557A1 (en) 2001-05-01 2002-11-11 The Regents Of The University Of California Wnt and frizzled receptors as targets for immunotherapy in head and neck squamous cell carcinomas
WO2003004045A2 (en) 2001-07-05 2003-01-16 Xenon Genetics, Inc. Methods for identifying therapeutic agents for treating diseases involving wnt polypeptides and wnt receptors
AU2002337657A1 (en) 2001-07-25 2003-02-17 Millennium Pharmaceuticals, Inc. Novel genes, compositions, kits, and methods for identification, assessment, prevention, and therapy of prostate cancer
EP1549144A4 (en) * 2002-10-04 2010-01-06 Univ California METHOD FOR THE TREATMENT OF CANCER BY INHIBITION OF THE WNT SIGNALING LINE
AU2003293408A1 (en) * 2002-12-06 2004-06-30 The Board Of Trustees Of The Leland Stanford Junior University PROTECTION OF STEM CELLS FROM CYTOTOXIC AGENTS BY MODULATION OF Beta-CATENIN SIGNALING PATHWAYS
US7803783B2 (en) 2002-12-06 2010-09-28 The Board Of Trustees Of The Leland Stanford Junior University Use of WNT inhibitors to augment therapeutic index of chemotherapy
US20050096263A1 (en) 2003-10-30 2005-05-05 Keay Susan K. Novel antiproliferative factor and methods of use
WO2006036175A2 (en) 2004-09-21 2006-04-06 Rhode Island Hospital, A Lifespan-Partner Wnt proteins and detection and treatment of cancer
WO2006034328A2 (en) 2004-09-21 2006-03-30 Rhode Island Hospital, A Lifespan-Partner Wnt proteins and detection and treatment of cancer
US7867705B2 (en) * 2004-09-21 2011-01-11 Rhode Island Hospital, A Lifespan-Partner Frizzled proteins and detection and treatment of cancer
WO2006055635A2 (en) 2004-11-15 2006-05-26 Mount Sinai School Of Medicine Of New York University Compositions and methods for altering wnt autocrine signaling
US7723477B2 (en) 2005-10-31 2010-05-25 Oncomed Pharmaceuticals, Inc. Compositions and methods for inhibiting Wnt-dependent solid tumor cell growth

Also Published As

Publication number Publication date
TW200819463A (en) 2008-05-01
MA31135B1 (fr) 2010-02-01
NO20091413L (no) 2009-06-08
US20170349639A1 (en) 2017-12-07
US20080299136A1 (en) 2008-12-04
EP2061495A2 (en) 2009-05-27
PE20120807A1 (es) 2012-07-26
KR20090060334A (ko) 2009-06-11
US20100266593A1 (en) 2010-10-21
AR062709A1 (es) 2008-11-26
RU2009113023A (ru) 2010-10-20
WO2008031009A3 (en) 2009-07-02
SG174100A1 (en) 2011-09-29
BRPI0714751A2 (pt) 2014-06-24
CA2662041A1 (en) 2008-03-13
PE20120806A1 (es) 2012-07-25
PE20081217A1 (es) 2008-09-24
US20110311534A1 (en) 2011-12-22
SG174101A1 (en) 2011-09-29
WO2008031009A2 (en) 2008-03-13
US20120141481A1 (en) 2012-06-07
US7947277B2 (en) 2011-05-24
MX2009002522A (es) 2009-06-19
JP2010504081A (ja) 2010-02-12
CL2007002609A1 (es) 2008-04-18
AU2007292242A1 (en) 2008-03-13
IL197240A0 (en) 2011-08-01

Similar Documents

Publication Publication Date Title
NL301192I2 (nl) Finerenon en zijn zouten, solvaten en solvaten van de zouten daarvan
IL197240A0 (en) Wnt antagonists and their use in the diagnosis and treatment of wnt-mediated disorders
PL2468290T3 (pl) Antagoniści aktywiny-ActRII do stosowania w leczeniu niedokrwistości
EP2022901A4 (en) DRYING MECHANISM AND SANITARY RINSING APPARATUS COMPRISING SAME
CR10847A (es) Compuesto heteromonociclico y uso del mismo
HUE038588T2 (hu) IL-22 mikrobiális rendellenességek kezelésében történõ alkalmazásra
IL202424A (en) Telomerase activating compounds for use in treating diseases, disorders and conditions related thereto
EP2215049A4 (en) P2x3, receptor antagonists for treatment of pain
HUE043175T2 (hu) Szintetikus triterpenoidok és alkalmazásuk betegség kezelésében
BRPI0909954A2 (pt) "diazacarbazóis e métodos de uso"
CL2007003672A1 (es) Compuestos derivados de heteroaril-pirrolidinil-cetona y heteroaril-piperidinil-cetona; composicion farmaceutica; y uso en el tratamiento de la depresion y ansiedad.
CL2007002327A1 (es) Compuestos derivados de fenil-imidazol sustituido; composicion farmaceutica; y uso en el tratamiento del vhc.
ATE531720T1 (de) Aza-benzofuranylverbindungen und anwendungsverfahren dafür
EP2215048A4 (en) ANTAGONISTS OF THE P2X3 RECEPTOR FOR THE TREATMENT OF PAIN
PL2314524T3 (pl) Urządzenie rozpylające oraz sposób użycia urządzenia rozpylającego
BRPI0817298A2 (pt) Combinações de substâncias ativas com propriedades inseticidas e acaricidas
BRPI0919903A2 (pt) dispositivo de mobilização corporal e utilização do dispositivo
CR10725A (es) Compuestos de pirazolina y su uso y composiones farmaceuticas
CL2007002207A1 (es) Compuestos derivados de sulfonilaminas; composicion farmaceutica; y uso de los compuestos en el tratamiento del glaucoma.
EP2218499A4 (en) MICROCHIP, MICROCHIP DEVICE, AND EVAPORATION OPERATION METHOD USING THE MICROCHIP
CL2007003038A1 (es) Compuestos derivados de 2-fenil-6-aminocarbonil-pirimidina; composicion farmaceutica; y uso en el tratamiento de trastornos vasculares oclusivos.
PL2839836T3 (pl) Probiotyki do zastosowania przy redukowaniu objawów choroby układu oddechowego
DK2124997T3 (da) Anvendelse af IL-1-antagonister til behandling af gigt og pseudogigt
BRPI0810475A2 (pt) uso de dimiracetam no tratamento de dor crônica
CR10430A (es) Aminothiazoles and their uses